Synergy Pharmaceuticals (SGYP) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for Synergy Pharmaceuticals (NASDAQ: SGYP):

  • 3/16/2017 – Synergy Pharmaceuticals was given a new $18.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 3/7/2017 – Synergy Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. “
  • 3/3/2017 – Synergy Pharmaceuticals had its “buy” rating reaffirmed by analysts at Rodman & Renshaw. They now have a $18.00 price target on the stock.
  • 3/2/2017 – Synergy Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Guggenheim. They now have a $10.00 price target on the stock.
  • 3/2/2017 – Synergy Pharmaceuticals was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 3/2/2017 – Synergy Pharmaceuticals was given a new $13.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 1/31/2017 – Synergy Pharmaceuticals had its “outperform” rating reaffirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.
  • 1/28/2017 – Synergy Pharmaceuticals had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $13.00 price target on the stock.
  • 1/27/2017 – Synergy Pharmaceuticals was given a new $18.00 price target on by analysts at HC Wainwright. They now have a “buy” rating on the stock.
  • 1/26/2017 – Synergy Pharmaceuticals had its “positive” rating reaffirmed by analysts at BTIG Research. They now have a $11.00 price target on the stock.
  • 1/26/2017 – Synergy Pharmaceuticals was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. “
  • 1/25/2017 – Synergy Pharmaceuticals was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $6.50 price target on the stock. According to Zacks, “Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. “
  • 1/21/2017 – Synergy Pharmaceuticals was given a new $10.00 price target on by analysts at Oppenheimer Holdings Inc.. They now have a “buy” rating on the stock.
  • 1/21/2017 – Synergy Pharmaceuticals was given a new $13.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 1/20/2017 – Synergy Pharmaceuticals had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $11.00 price target on the stock.
  • 1/20/2017 – Synergy Pharmaceuticals had its price target raised by analysts at Rodman & Renshaw from $17.00 to $18.00. They now have a “buy” rating on the stock.

Synergy Pharmaceuticals Inc (NASDAQ:SGYP) opened at 5.09 on Tuesday. Synergy Pharmaceuticals Inc has a 12 month low of $2.50 and a 12 month high of $7.15. The stock’s market cap is $1.14 billion. The stock’s 50 day moving average price is $5.85 and its 200-day moving average price is $5.53.

Synergy Pharmaceuticals (NASDAQ:SGYP) last announced its quarterly earnings results on Wednesday, March 1st. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by $0.11. Analysts anticipate that Synergy Pharmaceuticals Inc will post ($0.49) EPS for the current fiscal year.

Synergy Pharmaceuticals Inc (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company’s GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease.

5 Day Chart for NASDAQ:SGYP

Receive News & Ratings for Synergy Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synergy Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brazil Looks to Calm Fears Over Export and Sale of Meat
Brazil Looks to Calm Fears Over Export and Sale of Meat
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Dollar General Increasing Pay, Lowering Price and Adding Perishable Goods
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Euronet Worldwide Tops Offer by Ant to Acquire MoneyGram
Oil Prices Drop to Low of Three Months on Rig Count
Oil Prices Drop to Low of Three Months on Rig Count
Shares of Staples Fall After Earnings Come Up Short
Shares of Staples Fall After Earnings Come Up Short
Trump Tweet Sends Pharmaceutical Stocks Tumbling
Trump Tweet Sends Pharmaceutical Stocks Tumbling


Leave a Reply

© 2006-2017 Ticker Report. Google+.